Literature DB >> 15337694

Plasma levels of cholesteryl ester transfer protein and the risk of future coronary artery disease in apparently healthy men and women: the prospective EPIC (European Prospective Investigation into Cancer and nutrition)-Norfolk population study.

S Matthijs Boekholdt1, Jan-Albert Kuivenhoven, Nicholas J Wareham, Ron J G Peters, J Wouter Jukema, Robert Luben, Sheila A Bingham, Nicholas E Day, John J P Kastelein, Kay-Tee Khaw.   

Abstract

BACKGROUND: Low plasma levels of cholesteryl ester transfer protein (CETP) are associated with elevated levels of HDL cholesterol (HDL-C), but it remains unclear whether this translates into a concomitant reduction in the risk of coronary artery disease (CAD). Evidence exists that the effect of CETP depends on metabolic context, in particular on triglyceride levels. METHODS AND
RESULTS: A nested case-control study was performed in the prospective EPIC-Norfolk cohort study. Cases were apparently healthy men and women aged 45 to 79 years who developed fatal or nonfatal CAD during follow-up. Control subjects were matched by age, sex, and enrollment time. CETP levels were not significantly different between cases and controls (4.0+/-2.2 versus 3.8+/-2.1 mg/L, P=0.07). CETP levels were significantly related to plasma levels of total cholesterol, LDL cholesterol, and HDL-C. The risk of CAD increased with increasing CETP quintiles (P for linearity=0.02), such that subjects in the highest quintile had an adjusted OR of 1.43 (95% CI 1.03 to 1.99, P=0.03) versus those in the lowest. Among individuals with triglyceride levels below the median (1.7 mmol/L), no relationship between CETP levels and CAD risk was observed (P for linearity=0.5), but this relationship was strong among those with high triglyceride levels (P for linearity=0.02), such that those in the highest CETP quintile had an OR of 1.87 (95% CI 1.06 to 3.30, P=0.02).
CONCLUSIONS: Elevated CETP levels are associated with an increasing risk of future CAD in apparently healthy individuals, but only in those with high triglyceride levels.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15337694     DOI: 10.1161/01.CIR.0000141730.65972.95

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  39 in total

Review 1.  Cardiovascular disease risk reduction by raising HDL cholesterol--current therapies and future opportunities.

Authors:  K Mahdy Ali; A Wonnerth; K Huber; J Wojta
Journal:  Br J Pharmacol       Date:  2012-11       Impact factor: 8.739

Review 2.  Raising high-density lipoprotein cholesterol: innovative strategies against an old adversary.

Authors:  Dhruv Kazi; John A Farmer
Journal:  Curr Atheroscler Rep       Date:  2005-03       Impact factor: 5.113

Review 3.  Molecular regulation of HDL metabolism and function: implications for novel therapies.

Authors:  Daniel J Rader
Journal:  J Clin Invest       Date:  2006-12       Impact factor: 14.808

4.  Cholesteryl ester transfer protein alters liver and plasma triglyceride metabolism through two liver networks in female mice.

Authors:  Brian T Palmisano; Thao D Le; Lin Zhu; Yoon Kwang Lee; John M Stafford
Journal:  J Lipid Res       Date:  2016-06-27       Impact factor: 5.922

Review 5.  Coronary heart disease and polymorphisms in genes affecting lipid metabolism and inflammation.

Authors:  François Cambien
Journal:  Curr Atheroscler Rep       Date:  2005-05       Impact factor: 5.113

6.  Cholesteryl ester transfer protein, coronary calcium, and intima-media thickness of the carotid artery in middle-age Japanese men.

Authors:  Tomonori Okamura; Akira Sekikawa; Takashi Kadowaki; Aiman El-Saed; Robert D Abbott; J David Curb; Daniel Edmundowicz; Yasuyuki Nakamura; Kiyoshi Murata; Atsunori Kashiwagi; Kim Sutton-Tyrrell; Rhobert W Evans; Joseph M Zmuda; Hiroshi Maegawa; Atsushi Hozawa; Ken-Ichi Mitsunami; Yoshihiko Nishio; Iva Miljkovic-Gacic; Minoru Horie; Naomi Miyamatsu; Yoshitaka Murakami; Lewis H Kuller; Hirotsugu Ueshima
Journal:  Am J Cardiol       Date:  2009-07-18       Impact factor: 2.778

Review 7.  Novel HDL-directed pharmacotherapeutic strategies.

Authors:  Emil M Degoma; Daniel J Rader
Journal:  Nat Rev Cardiol       Date:  2011-01-18       Impact factor: 32.419

Review 8.  The role of CETP inhibition in dyslipidemia.

Authors:  Karim El Harchaoui; Wim A van der Steeg; Erik S G Stroes; John J P Kastelein
Journal:  Curr Atheroscler Rep       Date:  2007-08       Impact factor: 5.113

9.  Association of circulating cholesteryl ester transfer protein activity with incidence of cardiovascular disease in the community.

Authors:  Ramachandran S Vasan; Michael J Pencina; Sander J Robins; Justin P Zachariah; Guneet Kaur; Ralph B D'Agostino; Jose M Ordovas
Journal:  Circulation       Date:  2009-12-15       Impact factor: 29.690

10.  Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial.

Authors:  Evan A Stein; Eli M Roth; James M Rhyne; Tracy Burgess; David Kallend; Jennifer G Robinson
Journal:  Eur Heart J       Date:  2010-01-22       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.